WASHINGTON (dpa-AFX) - Watson Pharmaceuticals, Inc. (WPI) said its subsidiary Watson Laboratories, Inc., has received approval from the FDA for its Abbreviated New Drug Application, or ANDA, for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
One-Step is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.
Copyright RTT News/dpa-AFX